Prognostic Factors Of Adults B-Cell Acute Lymphoblastic Leukemia

Fouad, Dina Adel; Abo- El Wafa, Hasnaa Ahmed; Allam, Ahmed Ahmed; Aziz, Shereen. Philip; Mokhtar, Nesma

doi:10.21608/smj.2017.41390

Prognostic Factors Of Adults B-Cell Acute Lymphoblastic Leukemia

Document Type : Original Article

Authors

¹ Department of Clinical Pathology, Faculty of Medicine, Ain Shams University

² Department of Clinical Pathology,Faculty of Medicine, Sohag University.

³ Department of clinical and chemical pathology, Sohag Faculty of Medicine, Sohag University.

⁴ Department of Clinical and Pathology,sohag faculty of medicine,sohag university

10.21608/smj.2017.41390

Abstract

Background. B-cell acute lymphoblastic leukemia (B-ALL) is a malignancy of immature B-cell precursors that proliferate in the bone marrow leading to signs and symptoms of bone marrow failure. Clinical, biological and genetic features are having prognostic significance affecting the outcome of those patients. We aimed with this study to analyze the significance of these factors in affecting patients outcome after treatment with complete or incomplete remission.
Patients and methods. This study was carried out on 39 adults B-cell ALL patients who were attending the hematology oncology clinics. All patients were subjected to; History, clinical examination and Laboratory investigations, which included CBC, PB and BM examination, Immunophenotyping and Fluorescence in situ hybridization.
Results. This study was carried out on 39 adult B-cell ALL patients ( Follow up was done at day 28 of chemotherapy) show: 16 (41%) patients achieved complete remission (CR) ; while 23 (59%) patients showed incomplete remission (IR). Statistical analysis of patients’ outcome with prognostic markers revealed significant association (p<0.05) of CR with TLC <50x109/L (p=0.003) , age Conclusion. Age, TLC and t(9;22) are represent the most significant standard prognostic factors in relation to adults B-ALL patients' outcome.

References

Paul Shilpa, Hagop K and Elias J. (2016): "Adult Acute Lymphoblastic Leukemia." Mayo Clinic Proceedings 91.11 , 1645-666.

2.Sanam Loghavi, Jeffery L. Kutok and Jeffrey L. Jorgensen. (2015): “B-Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma .” American Journal of Clinical Pathology, vol. 144, no. 3, pp. 393–410., doi:org/10.1309/AJCPAN7BH5DNYWZB.

3.Ustwani, Omar Al , Neha Gupta, Hatoon Bakhribah, Elizabeth Griffith and Eunice Wang, Meir Wetzler. (2016): “Clinical updates in adult acute lymphoblastic leukemia.” Critical Reviews in Oncology/Hematology, vol. 99, 2016, pp. 189–199., doi:10.1016/j.critrevonc.

4.Stams W, Denboer M. and Beverloo H (2005): Expression levels of TEL-AML1 and AML-TEL versus drug sensititvity and clinical outcome in t(21, 21) positive pediatric acute lymphoblastic leukemia. Clin. Cancer Res., 11(8):2974.

5. Satake Noriko,Vikramjit S Kanwar, Jennifer Reikes Willert, Timothy P Cripe and Stephan A Grupp. (2017) ; “Pediatric Acute Lymphoblastic Leukemia.” Practice Essentials, Background, Pathophysiology, emedicine. medscape.com/article/990113-overview.

6. Sallam T, El-Telbany M, Mahmoud H and Iskander M (2013): Significance of Neutopilin-1 Experession in Acute Leukemia. Turk JHaematol. 30: 300-306.

7.Ilana de France, Rui Milton P, Audrey Violeta M, Washington B, Fárida C and Raul A. (2014): “Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia.” Fundac¸ão de Hematologia e Hemoterapia de Pernambuco (HEMOPE), vol. 36, no. 5, 18 July 2014, pp. 351–355., doi:org/10.1016/j.bjhh.2014.07.016.

8.Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M and Peruta B (2009):Improved risk classification for risk-specific therapybased on the molecular study of minimal residual disease(MRD) in adult acute lymphoblastic leukemia (ALL). Blood.2009;113(18):4153–62.

9. Aldoss I, Tracey S, Vinod P, Joycelynne P and Stephen F (2015): “The prognostic significance of additional cytogenetic abnormalities in adults with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplant.” Clinical Lymphoma Myeloma and Leukemia, vol. 15, doi:10.1016/j.clml.2015.04.012.